The Pharma Data

JULY 29, 2021

Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. In June 2021, Lilly announced the U.S. vice president of pain and neurodegeneration, Lilly.

Disease 52

Disease Pharmacokinetics Treatment FDA 52

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Bayer recently formed its own cell and gene therapy platform as part of its transformation strategy for Pharmaceuticals. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

Drug Discovery World

APRIL 25, 2024

The market for cell line development is currently rising due to an increased focus by the life sciences sector on biopharmaceuticals and targeted therapies. billion in 2022, a figure that is expected to grow at a compound annual growth rate (CAGR) of 9.81% from 2023 to 2030 1.

Vaccine 147

Vaccine Production Pharmaceuticals Therapies 147

The Pharma Data

NOVEMBER 5, 2020

Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Oncology Program. 50% PD-L1 expression. In millions).

Production 52

Production FDA FDA Approval Trials 52

The Pharma Data

MARCH 11, 2021

Sustainability forms an integral part of Bayer’s business strategy, growth plans and incentive systems, Baumann stressed, citing as an example the company’s decision to become carbon-neutral by 2030. Last year alone, the company concluded more than 25 collaboration and licensing agreements and acquisitions in its Pharmaceuticals Division.

Science 52

Science Pharmaceuticals Licensing Licensing 52

The Pharma Data

FEBRUARY 8, 2021

At the end of 2020, Dupixent ® was launched in 47 countries with approximately 230 000 patients on therapy. District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which lasts until October 2030. In 2020, Dupixent ® sales reached €3,534 million, up 73.9%

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

At the end of 2020, Dupixent ® was launched in 47 countries with approximately 230 000 patients on therapy. District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which lasts until October 2030. In 2020, Dupixent ® sales reached €3,534 million, up 73.9%

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

APRIL 27, 2021

At the end of the first quarter, Dupixent ® was launched in 49 countries with approximately 260 000 patients on therapy. . to €24 million, primarily due to the COVID-19 pandemic, which has led to a decrease in infused immune reconstitution therapies such as Lemtrada ®. Neurology and Immunology. Net sales (€ million). Change at CER.

Vaccine 52

Vaccine Production FDA FDA Approval 52